Skip to main content

Table 2 Hazard ratio (HR) of relapse of ER-positive postmenopausal breast cancer patients for median (0.403 ng/mL), third quartile (0.532 ng/mL) and 95% percentile (0.782 ng/mL) with respect to the first quartile (0.278 ng/mL) of testosterone levels, according to BMI groups

From: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients

Testosteronea level (ng/mL) BMI < 25 BMI 25–30 BMI ≥30
HRb (95% CI) HRb (95% CI) HRb (95% CI)
0.403 versus 0.278 5.52 (1.65–18.49) 1.64 (0.69–3.91) 0.68 (0.40–1.14)
0.532 versus 0.278 4.55 (1.09–18.98) 2.45 (0.75–8.02) 0.61 (0.31–1.20)
0.782 versus 0.278 0.25 (0.01–6.55) 4.68 (1.39–15.70) 0.75 (0.22–2.55)
  1. aTestosterone levels were included as a continuous variable into the model
  2. bTumour size and the number of metastatic lymph nodes were included in the Cox proportional hazard regression model as adjusting covariates. In parenthesis, pertinent 95% confidence interval